Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Braybrooke, Jeremy; Bradley, Rosie; Gray, Richard; Hills, Robert Kerrin; Pan, Hongchao; Pető, Richárd; Dodwell, David; McGale, Paul; Taylor, Carolyn; Aihara, Tomohiko; Anderson, Stewart J.; Blum, Joanne L.; Cardoso, Fátima; Chen, Xiaosong; Crown, John; Ejlertsen, Bent; Friedl, Thomas W. P.; Harbeck, Nadia; Janni, W; Jensen, Maj‐Britt; Mamounas, E.; Narui, Kazutaka; Nitz, Ulrike; Norton, Larry; O’Shaughnessy, Joyce; Piccart, Martine; Robert, Nicholas J.; Shao, Zhi‐Ming; Slamon, Dennis; Sparano, Joseph A.; Watanabe, Tôru; Yothers, Greg; Yu, Ke-Da; Berry, Richard M.; Boddington, Clare; Clarke, Mike; Davies, Christina; Davies, Lucy; Duane, F.; Evans, Vaughan; Gay, Jo; Gettins, Lucy; Godwin, Jon; James, Sam; Lui, Hui; Lui, Zulian; MacKinnon, Elizabeth; Mannu, Gurdeep; McHugh, Theresa; Morris, Philip; Read, Simon; Straiton, Ewan; Buzdar, Aman U.; Suman, Vera J.; Hunt, Kelly K.; Leonard, Robert; Mansi, Janine; Delbaldo, Catherine; Piedbois, Pascal; Quinaux, Emmanuel; Fesl, Christian; Gnant, Michael; Sölkner, Lidija; Steger, Guenther G.; Eikesdal, Hans Petter; Lønning, Per Eystein; Bée, Valerie; Fung, H; Mackey, John R.; Martín, Miguel; Press, Michael F.; Azambuja, Evandro de; Gelber, Richard D.; Regan, Meredith M.; Leo, Angelo Di; Dooren, Veerle Van; Nogaret, Jean Marie; Bartlett, John M.S.; Chen, Bingshu E.; Gelmon, Karen A.; Goss, Paul E.; Levine, Mark; Parulekar, Wendy R.; Pritchard, Kathleen I.; Shepherd, Lois E.; Berry, Donald A.; Cirrincione, Constance; Shulman, Lawrence N.; Winer, Eric P.; Gelman, Rebecca; Harris, Jay R.; Henderson, Craig; Shapiro, Charles L.; Christiansen, Peer; Ewertz, Marianne; Mouridsen, Henning T.; Leeuwen, Evert van; Linn, Sabine C.; Rossum, Annelot G.J. van; Tinteren, Harm van; Werkhoven, Erik van; Goldstein, Lori J.; Gray, Robert P.; Eiermann, W.; Gianni, Luca; Valagussa, Pinuccia; Bogaerts, Jan; Bonnefoi, Hervé; Poncet, Coralie; Huovinen, Riikka; Joensuu, Heikki; Bonneterre, Jacques; Fargeot, P.; Fumoleau, P.; Kerbrat, Pierre; Luporsi, É.; Namer, M.; Carrasco, Eva; Seguí, Miguel Àngel; Meisner, Christoph; Loibl, Sibylle; Nekljudova, Valentina; Thomssen, Christoph; Minckwitz, Gϋnter von; Kümmel, Sherko; Lopez, Massimo; Vici, Patrizia; Fountzilas, George; Koliou, G.-A.; Mavroudis, Dimitriοs; Saloustros, Emmanouil; Brain, Étienne; Delaloge, Suzette; Michiels, Stefan; Mathoulin‐Pélissier, Simone; Bines, José; Sarmento, Roberta M B; Bonadonna, Gianni; Brambilla, Cristina; Rossi, Anna; Bliss, Judith; Coombes, R. Charles; Kilburn, Lucy; Marty, M.; Amadori, Dino; Boccardo, Francesco; Nanni, Oriana; Rubagotti, Alessandra; Scarpi, Emanuela; Masuda, Norikazu; Toi, Masakazu; Ueno, Takayuki; Ishikawa, Takashi; Matsumoto, Koji; Takao, Shintaro; Sommer, H.; Foroglou, Pericles; Giokas, Georgios; Kondylis, D.; Lissaios, B; Reinisch, Mattea; Lee, Keun Seok; Nam, Byung–Ho; Ro, Jung Sil; Matteis, A. De; Perrone, Francesco; Tang, Gong; Wolmark, Norman; Hozumi, Yasuo; Nomura, Yasuo; Earl, Helena; Hiller, Louise; Vallier, Anne-Laure; Mastro, Lucia Del; Venturini, M.; Delozier, T.; Lemonnier, Jérôme; Martin, Anne‐Laure; Roché, Henri; Spielmann, M.; Chen, Xiasong; Shen, Kunwei; Albain, Kathy S.; Barlow, William E.; Budd, G. Thomas; Gralow, Julie R.; Hayes, Daniel; Bartlett-Lee, Peter; Ellis, Paul; Bianco, Angelo Raffaele; Laurentiis, Michelino De; Placido, Sabino De; Wildiers, Hans; Hsu, Limin; Eremin, O.; Walker, Leslie G.; Ahlgren, Johan; Blomqvist, Carl; Holmberg, Lars; Lindman, Henrik; Asmar, Lina; Jones, Stephen E.; Gluz, Oleg; Liedtke, Cornelia; Arriagada, R.; Bergsten-Nordström, Elizabeth; Carey, Lisa A.; Coleman, Robert E.; Cuzick, Jack; Davidson, Nancy E.; Dignam, James J.; Dowsett, Mitch; Francis, Prudence A.; Goetz, Matthew P.; Goodwin, Pam; Halpin-Murphy, Pat; Hill, Catherine; Jagsi, Reshma; Mukai, Hirofumi; Ohashi, Yasuo; Pierce, Lori J.; Poortmans, Philip; Raina, Vinod; Rea, Daniel; Robertson, J. F. R.; Rutgers, Emiel J.; Salgado, Roberto; Španić, Tanja; Tutt, Andrew; Viale, Giuseppe; Wang, Xiang; Whelan, Timothy J.; Wilcken, Nicholas; Cameron, David; Bergh, Jonas; Swain, Sandra M.

doi:10.1016/s0140-6736(23)00285-4

Cited by 50 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lancet 2023;401:1277-1292. 5 This is a meta-analysis of studies comparing the use of anthracyclines plus taxanes versus taxanes alone, in patients with early-stage breast cancer. There were 23 studies with 19,434 women.…”

Section: Anthracycline-containing and Taxane-containing Chemotherapy ...mentioning

confidence: 99%

Spotlight in Plastic Surgery: October 2023

Phillips,

Bollard,

Chang

et al. 2023

Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Section: Anthracycline-containing and Taxane-containing Chemotherapy ...mentioning

confidence: 99%

Spotlight in Plastic Surgery: October 2023

Phillips,

Bollard,

Chang

et al. 2023

Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

“…A priori dose reduction or omission of drugs is strongly discouraged, as retaining dose intensity and density is clearly associated with improved outcomes in early BC. 24 , 25 , 26 Granulocyte colony‐stimulating factors have a critical role in retaining dose intensity, 27 and available evidence shows that their administration during pregnancy is likely safe, although rare adverse events of in utero exposure to these agents cannot be ruled out. 17 , 28 Key agents, such as anthracyclines and cyclophosphamide, likely taxanes and carboplatin, can be safely administered to pregnant patients after the first trimester, with no apparent increase in neonatal complications.…”

Section: Treatment Approach To Pregnancy‐related Breast Cancermentioning

confidence: 99%

“…Nevertheless, regimens containing both anthracyclines and taxanes given in a dose‐dense schedule are the most effective options according to the latest two meta‐analyses from the Early Breast Cancer Trialists' Collaborative Group. 25 , 26 Moreover, the addition of carboplatin to neoadjuvant chemotherapy for triple‐negative BC is associated with improved pathologic complete response rates and event‐free survival, and so is standard of care at this setting. 33 …”

Section: Treatment Approach To Pregnancy‐related Breast Cancermentioning

confidence: 99%

Breast cancer during pregnancy—The oncologist's point of view

Matikas,

Bergh

2023

Acta Obstet Gynecol Scand

Self Cite

View full text Add to dashboard Cite

Breast cancer is the most common malignancy diagnosed during or directly after pregnancy. Differences in pathogenesis and prognosis identify two distinct patient groups, those with breast cancer during pregnancy and those with postpartum breast cancer which, for reasons not completely understood, is associated with worse outcomes. Compared with breast cancer in the non‐pregnant patient, several limitations in terms of both local and systemic therapy are applied to limit fetal harm. Treatment is nevertheless delivered with curative intent, therefore avoiding harmful delays in therapy initiation, unnecessary therapy de‐escalation or chemotherapy dose modifications is strongly recommended. In this short commentary, we briefly review current evidence and treatment guidelines and provide recommendations for optimal oncologic management of pregnancy‐related breast cancer.

show abstract

“…Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by the absence of the expression of receptors for estrogen (ER), progesterone (PR), and of human epidermal growth factor receptor-2 (HER2) [ 6 ]. Once diagnosed, treatment of TNBC relies on chemotherapy, in particular, on the anthracycline and taxane drugs [ 7 ], also in combination with other single agents such as gemcitabine [ 8 ] or capecitabine after surgery [ 9 ]. Generally, the median overall survival (OS) in patients with early stages of TNBC treated with chemotherapy is 13–18 months [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells

Giulietti,

Piva,

Cecati

et al. 2024

Cells

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are small lipid particles secreted by almost all human cells into the extracellular space. They perform the essential function of cell-to-cell communication, and their role in promoting breast cancer progression has been well demonstrated. It is known that EVs released by triple-negative and highly aggressive MDA-MB-231 breast cancer cells treated with paclitaxel, a microtubule-targeting agent (MTA), promoted chemoresistance in EV-recipient cells. Here, we studied the RNA content of EVs produced by the same MDA-MB-231 breast cancer cells treated with another MTA, eribulin mesylate. In particular, we analyzed the expression of different RNA species, including mRNAs, lncRNAs, miRNAs, snoRNAs, piRNAs and tRNA fragments by RNA-seq. Then, we performed differential expression analysis, weighted gene co-expression network analysis (WGCNA), functional enrichment analysis, and miRNA-target identification. Our findings demonstrate the possible involvement of EVs from eribulin-treated cells in the spread of chemoresistance, prompting the design of strategies that selectively target tumor EVs.

show abstract

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Cited by 50 publications

References 38 publications

Spotlight in Plastic Surgery: October 2023

Spotlight in Plastic Surgery: October 2023

Breast cancer during pregnancy—The oncologist's point of view

Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells

Contact Info

Product

Resources

About